These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33369425)

  • 41. Allosteric Binding Sites On Nuclear Receptors: Focus On Drug Efficacy and Selectivity.
    Fischer A; Smieško M
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics.
    Bartuzi D; Kaczor AA; Matosiuk D
    J Chem Inf Model; 2015 Nov; 55(11):2421-34. PubMed ID: 26517559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uncoupling of an ammonia channel as a mechanism of allosteric inhibition in anthranilate synthase of Serratia marcescens: dynamic and graph theoretical analysis.
    Srivastava A; Sinha S
    Mol Biosyst; 2016 Dec; 13(1):142-155. PubMed ID: 27833951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
    Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allosteric modulation of G protein-coupled receptors.
    May LT; Leach K; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2007; 47():1-51. PubMed ID: 17009927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allosteric sites can be identified based on the residue-residue interaction energy difference.
    Ma X; Qi Y; Lai L
    Proteins; 2015 Aug; 83(8):1375-84. PubMed ID: 25185787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Probing Protein Allostery as a Residue-Specific Concept via Residue Response Maps.
    Hayatshahi HS; Ahuactzin E; Tao P; Wang S; Liu J
    J Chem Inf Model; 2019 Nov; 59(11):4691-4705. PubMed ID: 31589429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
    Bian Y; Feng Z; Yang P; Xie XQ
    AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allostery in G protein-coupled receptors investigated by molecular dynamics simulations.
    Lamim Ribeiro JM; Filizola M
    Curr Opin Struct Biol; 2019 Apr; 55():121-128. PubMed ID: 31096158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning.
    Ferraro M; Decherchi S; De Simone A; Recanatini M; Cavalli A; Bottegoni G
    Eur J Med Chem; 2020 Feb; 188():111975. PubMed ID: 31940507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of mutations on the allosteric conformational equilibrium.
    Weinkam P; Chen YC; Pons J; Sali A
    J Mol Biol; 2013 Feb; 425(3):647-61. PubMed ID: 23228330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virtual screening of a natural compound library at orthosteric and allosteric binding sites of the neurotensin receptor.
    Rejwan Ali M; Sadoqi M; Boutajangout A; Mezei M
    J Biomol Struct Dyn; 2019 Oct; 37(17):4494-4506. PubMed ID: 30479178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators.
    Jakubík J; Randáková A; El-Fakahany EE; Doležal V
    PLoS One; 2019; 14(3):e0214255. PubMed ID: 30917186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NRIMD, a Web Server for Analyzing Protein Allosteric Interactions Based on Molecular Dynamics Simulation.
    He Y; Wang S; Zeng S; Zhu J; Xu D; Han W; Wang J
    J Chem Inf Model; 2024 Oct; 64(19):7176-7183. PubMed ID: 38991149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repositioning Dequalinium as Potent Muscarinic Allosteric Ligand by Combining Virtual Screening Campaigns and Experimental Binding Assays.
    Mazzolari A; Gervasoni S; Pedretti A; Fumagalli L; Matucci R; Vistoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors.
    Shang Y; Yeatman HR; Provasi D; Alt A; Christopoulos A; Canals M; Filizola M
    ACS Chem Biol; 2016 May; 11(5):1220-9. PubMed ID: 26841170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systems Approaches to Understanding and Designing Allosteric Proteins.
    Raman S
    Biochemistry; 2018 Jan; 57(4):376-382. PubMed ID: 29235352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hidden allosteric sites and De-Novo drug design.
    Rehman AU; Lu S; Khan AA; Khurshid B; Rasheed S; Wadood A; Zhang J
    Expert Opin Drug Discov; 2022 Mar; 17(3):283-295. PubMed ID: 34933653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
    Lu S; Zhang J
    J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allosteric interactions at muscarinic cholinoceptors.
    Christopoulos A; Lanzafame A; Mitchelson F
    Clin Exp Pharmacol Physiol; 1998; 25(3-4):185-94. PubMed ID: 9590567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.